Joint discomfort is not listed as a recognised adverse effect in the BNF or licensed B12 product information, and most people taking B12 experience no musculoskeletal symptoms
However, given the novelty of this therapeutic approach, the available evidence may be influenced by publication bias and early optimism, and long-term mechanistic and clinical outcome data remain limited
Through this management of GLP-1 use, Univera Healthcare has realized cost savings, as indicated by the graph below: Univera Healthcare is using what appears to be the most sensible weight loss GLP-1 prior authorization criteria in the marketplace, without significantly disrupting rebates. -USI Partner What we know about the future of GLP-1 drugs In 2024, there were significant advancements with GLP-1 indications
At Skinnyrx, a brief assessment can connect you with personalized resources and our physicians who specialize in weight loss.
[DOI] [PubMed] [Google Scholar] 19.Zhao X., Wang M., Wen Z., Lu Z., Cui L., Fu C., Xue H., Liu Y., Zhang Y
Pregnancy as a window to future health: excessive gestational weight gain and obesity
